Latest News

(UroToday.com) Multiple anti-PD-L1 therapies have been approved for use in 2nd line in patients with advanced urothelial carcinoma (UC), including pembrolizumab. The current standard of care first-line therapy for advanced UC is cisplatin-based chemotherapy. Avelumab is recommended as maintenance therapy in patients who do not progress on first-line platinum-based chemotherapy. Pembrolizumab and atezolizumab are recommended […]

(UroToday.com) Responses to immune checkpoint blockade in cancer therapy are heterogeneous, with a minority of patients experiencing sustained responses to therapy. The identification of predictive biomarkers for immunotherapy response is an area of intense research interest. In this presentation, Srikala Sridhar, MD, presented an assessment of potential biomarkers for response within the JAVELIN Bladder 100 […]

(UroToday.com) Treatment for patients with advanced bladder cancer has had some significant advances in the past few years. For many years, platinum-based chemotherapy has been standard of care, with significantly better outcomes among those able to tolerate cisplatin-based therapy than those who are cisplatin-ineligible. Since 2016, there has been a proliferation of treatment approaches including […]

(UroToday.com) Following the presentation from Dr. Toni Choueiri of the data from CheckMate 9ER, Dr. Camillo Guglielmo provided an invited discussion of this data.

(UroToday.com) Platinum-based chemotherapy remains the standard of care for the first-line treatment of metastatic urothelial cancer (UC). Despite yielding a high response rate, the survival outcomes for this disease remain low.1  Atezolizumab (anti-PDL1) and pembrolizumab (anti-PD1) have been approved for the first-line treatment of cisplatin-ineligible patients with metastatic UC and high tumor PD-L1 expression, based […]

(UroToday.com) This oral abstract provided data on patient-reported outcomes from Arm A (combination immunotherapy and platinum chemotherapy) versus Arm C (placebo + platinum chemotherapy) in the IMvigor130 study. The IMvigor130 study is a phase 3 randomized placebo-controlled trial investigating the clinical efficacy of atezolizumab (anti-PD-L1 antibody) versus combination atezolizumab and platinum chemotherapy versus chemotherapy alone […]

(UroToday.com) Treatment options for advanced urothelial cancer that has progressed through platinum chemotherapy and immune checkpoint blockade consist of (1) single agent chemotherapy, (2) FGFR inhibitor therapyfor tumors harboring susceptible alterations, and (3) the antibody-drug conjugate enfortumab vedotin. Sacituzumab govitecan is an antibody-drug conjugate containing an antibody against the epithelial cell surface molecule Trop-2 that is […]

(UroToday.com) The treatment landscape for first-line therapy among patients with metastatic renal cell carcinoma (mRCC) has changed dramatically over the past 2 years. In 2018, the publication of the CheckMate 214 data demonstrated a survival benefit for patients treated with nivolumab and ipilimumab compared with sunitinib in intermediate and poor-risk mRCC, ushering in the immunotherapy […]

Opdivo in combination with CABOMETYX showed superior overall survival and doubled median progression-free survival and objective response rate with a favorable safety profile vs. sunitinib Efficacy benefits were observed across key patient subgroups, including all International Metastatic Renal Cell Carcinoma Database Consortium risk and PD-L1 subgroups Data selected for presentation during a Presidential Symposium and featured in the […]

(UroToday.com) Metastatic castration-resistant prostate cancer (mCRPC) is associated with poor prognosis. mCRPC has well-known molecular heterogeneity, with approximately 25% of patients having defects in deoxyribonucleic acid (DNA) repair genes, most of which are homologous recombination repair mutations (HRRm), such as BRCA1, BRCA2, and ATM).1,2 There is a lack of individualized treatment options for patients harboring HRR […]